

Consun Pharmaceutical Group Limited

(康臣藥業集團有限公司)

(the “Company”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

BOARD DIVERISTY POLICY

1. PURPOSE

This Policy aims to set out the approach to achieve diversity on the Company’s board of directors (the “Board”).

2. VISION

The Company recognizes and embraces the benefits of having a diverse Board to enhance the quality of its performance.

3. POLICY STATEMENT

With a view to achieving a sustainable and balanced development, the Company sees increasing diversity at the Board level as an essential element in supporting the attainment of its strategic objectives and its sustainable development. All Board appointments will be based on meritocracy, and candidates will be considered against appropriate criteria, having due regard for the benefits of diversity on the Board.

4. IMPLEMENTATION

The Company commits to selecting the best person for the role. Selection of candidates will be based on a range of diversity perspectives, including but not limited to gender, age, cultural background and ethnicity, in addition to educational background, professional experience, skills, knowledge and length of service. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board. The Board’s composition (including gender, age, length of service) will be disclosed in the Corporate Governance Report annually.

5. MONITORING AND REPORTING

The Nomination Committee will report annually, in the Corporate Governance Report, on the Board’s composition under diversified perspectives, and monitor the implementation of this Policy.

6. REVIEW OF THIS POLICY

The Nomination Committee will review this Policy, as appropriate, to ensure the effectiveness of this Policy. The Nomination Committee will discuss any revisions that may be required, and recommend any such revisions to the Board for consideration and approval.

7. DISCLOSURE OF THIS POLICY

This Policy will be published on the Company's website for public information.

A summary of this Policy and the progress of implementing this Policy will be disclosed in the annual Corporate Governance Report.

2 December 2013